Last session of the day with a panel discussing 8CPA #pharmacyconnect2024

Achieve Life Sciences is pleased to announce two milestones: - The completion of enrollment for the ORCA-OL Clinical Trial, evaluating the long-term effects of our novel 3mg cytisinicline dosing regimen in individuals who smoke or vape nicotine. - The first Data Safety Monitoring Committee (DSMC) meeting to review the ORCA-OL trial was conducted. The DSMC concluded there are no safety concerns, the overall safety profile appears to be excellent, and the study may proceed as planned with no modifications. Learn more here: https://lnkd.in/eYZ3CXE6 #SmokingCessation #Smoking #Nicotine

Nitrosamine impurities pose a serious threat to drug product safety, with potential carcinogenic effects. Stay informed on the latest information and resources from USP for nitrosamine testing to ensure product quality and patient safety. Download USP’s new case study for Carcinogenic Potency Categorization Approach (CPCA) ??: https://ow.ly/lUNk50RYJgO #NitrosamineImpurities #ImpurityLimits #USPScience

If any of my LinkedIn colleague companies are looking to step up or enhance their medical, health & dental benefits, ask your brokers to tell you more about ClaimSecure and how they adjudicate claims. You will find it refreshingly simple & impactful, and did I say…….save money? Mitchell Hanlon, Dave Wowchuk

Connect with peers effortlessly for your revalidation needs! Simplify the process of finding and scheduling private discussions, on the C+D Community and make peer-to-peer engagement a seamless part of your journey. #C+DCommunity #PeerDiscussion #pharmacy https://ow.ly/UEhN50RQFEW

Have you gotten the May issue of my monthly newsletter, A Note from #BirdieTheBenefitsBoxer? It contains important information about upcoming ParetoHealth events, reminders, tips, industry updates and more! Comment below or shoot me a note if you’d like to get on the list. ?? #paretohealth #captives #benefitscaptives #newsletter #stoploss #pharmacy #membershipmatters #ProudlyContrarian

The IAHSS Council on Guidelines is requesting #memberfeedback on the new Drug Diversion guideline, 07.02.01. Please review the guideline and complete the survey by May 6, 2024. Share your thoughts by clicking the link provided ?? https://buff.ly/3vPAbvD #healthcaresafety #healthcaresecurity

??CALM by CODE helps balance the mind, promoting a sense of calmness and focus. Hear Ricky and Beth share their first-time experience using CALM in their testimonial. “After about an hour what we both noticed is that we feel a bit more relaxed, alert, more calm, and more aware of what was going on.” ~Ricky and Beth Bennett ??CALM is a drug free, non-toxic alternative to over the counter and prescription medications. ??To Learn More about CALM, and to read reviews by satisfied customers, Click Here??: https://lnkd.in/ekv2tipn ??Use the code VIP20 to save $20 off of CALM or your product of choice. #bioenergetictherapeutic #codehealth #holistichealth #drugfree #mentalhealth #nontoxic #frequencyhealing #energyhealing #CALMbyCODE Wendy Cohn Dr. Lisa Piper

Thoughts on this? >> FTC's Lina Khan and Mark Cuban headline White House listening session to rail against PBMs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #healthcare #biotech #pharmaceutical

The FDA has taken a bold step towards the potential removal of a staple decongestant from pharmacy shelves. The agency has proposed withdrawing oral phenylephrine, a common ingredient in popular over-the-counter medications like Sudafed PE, Vicks DayQuil, and Mucinex Sinus-Max, due to growing evidence questioning its effectiveness. This widely used nasal decongestant has been a go-to remedy for decades, but the FDA's announcement signals a significant shift. While this isn't an immediate ban, the proposal opens a six-month window for public commentary, allowing consumers and healthcare professionals to weigh in before a final decision is made. Will this beloved over-the-counter remedy soon be a thing of the past? https://lnkd.in/ec63Zwtp